Navigation Links
Actonel Treats Hip Fractures In A Better Way Than Alendronate

New study shows that osteoporosis patients treated with Actonel are more likely to sustain when compared to alendronate. //These results were published today in the peer-reviewed journal Osteoporosis International after collecting data from 33,000 women with osteoporosis.

The study of 33,000 postmenopausal women showed that among patients newly prescribed one of the two most popular osteoporosis treatments, patients taking Actonel? (risedronate sodium) were approximately half as likely to sustain a hip fracture as those taking alendronate in the first year of treatment. 'The rapid onset of fracture reduction observed for risedronate in this study is consistent with results from randomised clinical trials of risedronate,' says Professor Pierre Delmas, study author, Universite Claude Bernard, Lyon.

'Earlier fracture protection means that fewer patients will suffer the devastating consequences of an osteoporotic fracture, helping to both preserve patients' quality of life and to reduce the economic burden of healthcare.'

The REAL (RisedronatE, ALendronate) retrospective cohort study included 33,830 women newly treated with once-weekly doses of either Actonel or alendronate in 'real-life' clinical practice. Results showed that at six months patients on Actonel had a 46% (p=0.02) lower incidence of hip fractures compared to patients on alendronate. At 12 months similar results were seen, with Actonel resulting in a 43% (p=0.01) greater reduction in risk of hip fracture versus alendronate. The two treatments were not compared on the basis of side effects in this study.

This study adds to the body of evidence from randomised controlled trials demonstrating that Actonel exerts an early onset of fracture protection, seen as early as six months for clinical vertebral fracture and nonvertebral fractures. No other bisphosphonate treatments for osteoporosis have been shown in clinical trials to reduce clinical fractures this early for pat ients. However, data are limited that compare therapies directly in the same study on the basis of fracture reduction - the clinically important endpoint in osteoporosis treatment.

'In the osteoporosis field it is unlikely that prospective, head-to-head clinical fracture trials will be conducted due to the large number of patients required to show a difference between two effective therapies,' said Professor Delmas. 'Large, comparative, retrospective analyses, like the REAL study, are one way to fill the knowledge gap and should be considered in the total body of evidence for a drug to optimise treatment decisions and enhance patient care.'

Currently 1.6 million hip fractures occur worldwide per year, accounting for approximately €104 billion in worldwide annual healthcare costs. Among those patients who suffer a hip fracture, approximately one in five will die within the following year and 40% will be unable to walk independently one year later.

Source-Eurekalert
SRI
'"/>




Related medicine news :

1. First head-to-head trials of once weekly Fosamax and Actonel therapies
2. Cyclosporin A Treats Leukemia Complications
3. Weight Reduction Surgery Also Treats Metabolic Syndrome
4. Chennai Hospital Treats Pakistani Blue Baby
5. Cocoa Treats: Chocolates, as a Health Investment? Chew on this!
6. New Gene Therapy Treats Diabetic Neuropathy
7. BBIC – A SOY-based Substance Treats Multiple Sclerosi
8. Cake Walk – Plum Treats Sell Like Hot Cakes During Christma
9. Common BP Drug Treats Muscular Dystrophy
10. Naltrexone also Treats Crohns Disease
11. Drug for Blood Pressure also Treats Lung Cancer
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/25/2016)... ... June 25, 2016 , ... "With 30 hand-drawn hand gesture animations, ... Christina Austin - CEO of Pixel Film Studios. , ProHand Cartoon’s package transforms ... Final Cut Pro X . Simply select a ProHand generator and drag it above ...
(Date:6/25/2016)... ... June 25, 2016 , ... On Friday, June 10, Van Mitchell, Secretary of ... award to iHire in recognition of their exemplary accomplishments in worksite health promotion. , ... Workplace Health & Wellness Symposium at the BWI Marriott in Linthicum Heights. iHire was ...
(Date:6/24/2016)... Michigan (PRWEB) , ... June 24, 2016 , ... June ... about the dangers associated with chronic pain and the benefits of holistic treatments, ... individuals who are suffering with Sickle Cell Disease. , Sickle Cell Disease (SCD) is ...
(Date:6/24/2016)... ... 24, 2016 , ... Dr. Amanda Cheng, an orthodontist ... has extensive experience with all areas of orthodontics, including robotic Suresmile technology, ... , Micro-osteoperforation is a revolutionary adjunct to orthodontic treatment. It can be used ...
(Date:6/24/2016)... Norcross, Georgia (PRWEB) , ... June 24, 2016 ... ... Year” awards today at the Clinical Decision Making in Emergency Medicine conference in ... who have authored journal articles published in Emergency Medicine Practice and ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... 24, 2016   Bay Area Lyme Foundation ... Dean Center for Tick Borne Illness , Harvard ... MIT Hacking Medicine, University of California, Berkeley, and ... the five finalists of Lyme Innovation , ... than 100 scientists, clinicians, researchers, entrepreneurs, and investors ...
(Date:6/24/2016)... Mass. and SAN CLEMENTE, Calif. , ... California -based mobile pulmonary function testing company, is now able ... PFT devices developed by ndd Medical Technologies , Inc. ... testing done in hospital-based labs.  Thanks to ndd,s EasyOne PRO ® ... , can get any needed testing done in the comfort ...
(Date:6/24/2016)... Tenn. , June 24, 2016  Arkis ... providing less invasive and more durable cerebrospinal fluid ... in funding.  The Series-A funding is led by ... Lighthouse Fund, and other private investors.  Arkis, new ... neurosurgical instrumentation and the market release of its ...
Breaking Medicine Technology: